Zobrazeno 1 - 10
of 8 903
pro vyhledávání: ''
Autor:
Muath, Abdeen, Urwat Til, Vusqa, Palash, Asawa, Kiley, Felton, Derek, Rinchuse, Cyrus, Khan, Yazan, Samhouri, John, Lister
Publikováno v:
Anti-Cancer Drugs. 33:1167-1170
Venetoclax, a highly selective Bcl-2 inhibitor, is an orally bioavailable drug that has been approved as first-line therapy for chronic lymphocytic leukemia (CLL) in combination with obinutuzumab, as well as monotherapy in the setting of relapsed CLL
Autor:
Vieri Scotti, Beatrice Fantechi, Francesca Mazzoni, I. Stasi, Irene Pecora, Carmelo Tibaldi, Enrico Vasile, Chiara Caparello, Editta Baldini, Marianna Turrini, Lorenzo Antonuzzo, Francesca Federici, Andrea Camerini, Giulia Meoni, Daniele Pozzessere, Diana Giannarelli, Virginia Rossi, L.P. Ciccone
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:1278-1285
Background: In advanced non-small-cell lung cancer, without activating mutations and with PD-L1≥50%, Pembrolizumab monotherapy is the therapeutic standard in Europe. Objective: To evaluate retrospectively the safety and efficacy of this drug and to
Publikováno v:
Anti-Cancer Drugs. 33:534-538
The purpose of this study is to provide certain data on clinical outcome of primary androgen deprivation therapy in men over 80 years of age with localized high-risk prostate cancer. This study included 54 Japanese super-elderly men with high-risk pr
Autor:
Thorsten Lehr, Hannah Britz, Clinton F. Stewart, Daniel Moj, Walter E. Haefeli, Gerlinde Egerer, Jürgen Burhenne
This study aimed at recommending pediatric dosages of the histone deacetylase (HDAC) inhibitor vorinostat and potentially more effective adult dosing regimens than the approved standard dosing regimen of 400 mg/day, using a comprehensive physiologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b42701510c1983fe755fd57a7800a87
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
Louis B. Nabors, David A. Reardon, John Simes, Lisa Roberts-Rapp, Ho-Jin Lee, Nicholas Butowski, Tobias Walbert, Andrew B. Lassman, Helen Wheeler, Priya Kumthekar, Andrew M. Scott, Peter Ansell, Tom Mikkelsen, Marta Penas-Prado, Kyriakos P. Papadopoulos, Martin J. van den Bent, Earle Bain, Zarnie Lwin, Erica Gomez, David Maag, Ryan Merrell, Hui K Gan, Hao Xiong, Kyle D. Holen
Publikováno v:
Cancer Chemotherapy & Pharmacology, 80(6), 1209-1217. Springer-Verlag
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff65c6833473b7cdb380bda35882ca5
Autor:
Tsutomu, Yoshida, Go, Ogura, Mikiko, Tanabe, Takuo, Hayashi, Chiho, Ohbayashi, Mizutomo, Azuma, Chikara, Kunisaki, Yoichi, Akazawa, Soji, Ozawa, Sohei, Matsumoto, Takayoshi, Suzuki, Akira, Mitoro, Tetsu, Fukunaga, Akiko, Shimizu, Go, Fujimoto, Takashi, Yao
Publikováno v:
Cancer Biology & Therapy. 23:191-200
This real-world study examined the prevalence of programmed death ligand-1 (PD-L1) expression and assessed the frequency of microsatellite instability-high (MSI-H) status and Epstein-Barr virus (EBV) positivity in Japanese patients with advanced gast
Autor:
Satoshi, Fukata, Keisuke, Mizutani, Shinkuro, Yamamoto, Takahira, Kuno, Hideo, Fukuhara, Shingo, Ashida, Takashi, Karashima, Keiji, Inoue
Publikováno v:
Anti-Cancer Drugs. 33:459-466
The objective was to evaluate the usefulness of sarcopenia and the neutrophil/lymphocyte ratio (NLR) as therapeutic efficacy predictors in patients who received pembrolizumab after platinum-based chemotherapy for advanced urothelial carcinoma (aUC).
Autor:
Manon Reda, Pauline Macaire, Hélène Bellio, Lionel Uwer, Silvia Ilie, Véronique Lorgis, Audrey Hennequin, Sylvain Ladoire, Emilie Rederstorff, Pierre Fumoleau, Nicolas Isambert, Nathalie Bonnin, Benoit You, Gilles Freyer, Isabelle Desmoulins, Antonin Schmitt
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:197-208
Granulocyte colony-stimulating factors (G-CSF) are commonly given to limit chemotherapy-induced neutropenia, but, in case of weekly chemotherapy such as eribulin, their administration schedules remain empirical.This pharmacokinetic/pharmacodynamic (P
Autor:
Anne-Gaëlle Dosne, Elodie Valade, Nele Goeyvaerts, Peter De Porre, Anjali Avadhani, Anne O’Hagan, Lilian Y. Li, Daniele Ouellet, Juan Jose Perez Ruixo
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:151-164
Background Exposure–response analyses were conducted to explore the relationship between selected efficacy and safety endpoints and serum phosphate (PO4) concentrations, a potential biomarker of efficacy and safety, in locally advanced or metastati